

REDUCE HOSPITALIZATIONS WITH SMARTVEST

One in five patients hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD) will require rehospitalization within 30 days.¹ Of the **11 million patients** living with COPD², approximately half may have comorbid bronchiectasis.³

Consequently, the overlap of bronchiectasis and COPD is associated with more frequent exacerbations, reduced lung function, and increased mortality.³ SmartVest, a high frequency chest wall oscillation (HFCWO) therapy device, helps hospital teams and patients lower healthcare costs by reducing pulmonary readmissions.



BRONCHIECTASIS PREVALENCE IN COPD

Today, hospitals face heightened financial pressures to reduce COPD readmissions while improving quality of care. Curbing COPD readmissions requires a multidisciplinary approach to develop a comprehensive care management program, including:



Improvement of care transitions, from hospital to home



Follow-up post-discharge



Case-finding for comorbid bronchiectasis

Identifying comorbid bronchiectasis in COPD through a high-resolution CT scan will enable health care teams to effectively treat patients with appropriate and tailored therapy to increase healthcare savings, incur fewer penalties, and improve patients' quality of life.

smartvest[®]
AIRWAY CLEARANCE SYSTEM

¹ Tina Shah, MD, MPH; Valerie G. Press, MD, MPH; Megan Huisinigh-Scheetz, MD, MPH; and Steven R. White, MD. (2016) "COPD readmissions: Addressing COPD in the era of value-based health care." American College of CHEST Physicians, 150 (4), 916-926. Retrieved from [https://journal.chestnet.org/article/S0012-3692\(16\)48969-5/pdf](https://journal.chestnet.org/article/S0012-3692(16)48969-5/pdf)

² The American Lung Association. "How Serious is COPD." Retrieved from <https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/learn-about-copd/how-serious-is-copd.html>

³ Chalmers J. and Sethi S. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27:18.

BREAK THE CYCLE OF CHRONIC LUNG INFECTIONS

The SmartVest Airway Clearance System by Electromed is the only respiratory vest on the market with published evidence demonstrating improved outcomes in treating bronchiectasis.

59% Decrease
in hospitalizations



60% Decrease
in emergency department visits



68% Improved
quality of life in patients⁴

OUTSMART THE CYCLE OF READMISSION

By incorporating SmartVest into your continuum of care program, your hospital benefits from a solution designed to reduce pulmonary readmissions and a support team committed to helping you throughout the patient care journey.



CONFIRM DIAGNOSIS

Patient is admitted for pulmonary infection and receives HRCT scan to confirm bronchiectasis

PRESCRIBE AND DISCHARGE

Doctor prescribes SmartVest HFCWO therapy and discharges patient

IN-HOME PATIENT SUPPORT

Patient receives personalized, in-home training from a respiratory therapist on how to use SmartVest

THERAPY IS TRACKED

Patient independently performs therapy and treatment insights are reported via SmartVest Connect



SMART SAVINGS

Contact Electromed today, and we'll help support your continuum of care program to reduce hospital readmissions, improve patient outcomes, and achieve meaningful cost savings.

www.smartvest.com

⁴ Sievert CE, et al. 2016. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes-Based Case Review. Respiratory Therapy, 11(4), 34-38.